Compare Otis Worldwide Corp (OTIS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs GeneDx Holdings Corp — how do they compare? Otis Worldwide Corp trades at $65.98 (market cap $25.17B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Otis Worldwide Corp is far larger — about 12.5× GeneDx Holdings Corp's market cap, and Otis Worldwide Corp pays a 2.66% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Otis Worldwide Corp for 66 Days and GeneDx Holdings Corp for 19 Days on average.
| OTIS | WGS | |
|---|---|---|
Market Cap | $25.17B | $2.02B |
Volume | 4,542,442 | 734,640 |
Sector | Industrials | Health |
52-Week High | $93.62 | $167.51 |
52-Week Low | $64.05 | $34.51 |
Typical Hold Time | 66 Days | 19 Days |
Enterprise Value | $33.20B | $2.05B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Otis Worldwide trades at $65.95, showing modest daily gains of 0.32% but remains near its 52-week low. The stock faces technical bearish signals with mixed fundamental performance - revenue growth remains stable at $14.43B (2025) but recent quarters show earnings misses. Analyst consensus is divided with 7 buy, 7 hold, and 1 sell ratings, while the company navigates margin pressures and China market challenges.
The outlook balances Otis's dominant market position and service-driven cash flows against margin pressures and weak equipment demand. With a $87 consensus price target suggesting 32% upside, the stock offers value but requires monitoring of service margin recovery and China exposure. Key risks include persistent cost inflation and execution challenges in key markets.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
